Glucagon and GLP-1 receptor co-agonist
Mazdutide injection
MAZD_SC
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.33 (0.01 to 14.75) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 5.02 (0.31 to 151) | 0.25 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.49 (0.03 to 6.17) | 0.65 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.41 (0.13 to 1.16) | 0.86 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.17 (0.00 to 3.95) | 0.85 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.60 (1.19 to 5.90) | 0.39 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.75 (1.01 to 7.86) | 0.39 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.41 (2.30 to 8.80) | 0.11 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.71 (0.04 to 10.97) | 0.44 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.79 (0.05 to 12.30) | 0.51 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -6.22 (-15.24 to 2.99) | 0.74 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -12.29 (-17.93 to -6.47) | 0.87 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 49.66 (13.63 to 199) | 0.94 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 63.08 (10.72 to 618) | 0.94 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 25.65 (4.28 to 363) | 1.00 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.30 (0.80 to 75.59) | 0.19 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.25 (0.38 to 54.15) | 0.40 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 10.02 (3.92 to 34.90) | 0.13 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 9.02 (2.78 to 42.95) | 0.30 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.78 (1.27 to 6.98) | 0.33 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.13 (0.37 to 24.27) | 0.46 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.56 (0.32 to 149) | 0.34 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.43 (0.00 to 31.24) | 0.74 |
Trials
- NCT04965506A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes2021 · 252 randomized · 20 weeks
- NCT04904913A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects2021 · 248 randomized · 24 weeks
- NCT04466904A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control2020 · 43 randomized · 12 weeks